{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T14:10:09Z","timestamp":1752243009527,"version":"3.41.2"},"reference-count":30,"publisher":"University of Toronto Press Inc. (UTPress)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the Association of Medical Microbiology and Infectious Disease Canada"],"published-print":{"date-parts":[[2025,6,27]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p> Rifampin-resistant (RR) and multidrug-resistant (MDR) tuberculosis (TB) previously required treatment with a protracted course of toxic second-line TB drugs with suboptimal efficacy. Novel 6-month regimens of bedaquiline, pretomanid, linezolid with or without moxifloxacin (BPaL\/M) are now recommended, but implementation in Canada is not well described. <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p> We analyzed eight people with MDR or pre\u2013extensively drug-resistant (pre-XDR) TB or rifamycin intolerance treated with BPaL\/M in western Canada to inform expanded use. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p> The mean times to confirm first- and second-line phenotypic TB susceptibility profiles were 5 and 11 weeks, respectively. Time to start an effective treatment regimen took on average 5 weeks from date of diagnosis, and time to start BPaL\/M took 11 weeks due to medication approval, access, and delivery delays. The mean time to culture and smear conversion was 3 and 5 weeks, respectively, from the start of effective therapy. Individuals were isolated for a mean of 15 weeks with an average duration of hospitalization of 13 weeks. BPaL\/M medications were associated with minor toxicity, including mild non-progressive peripheral neuropathy (3 cases, CTCAE grade 2) and blood transfusion for anemia (3 cases, CTCAE grade 3), all managed by linezolid dose adjustments. The mean total treatment duration was 8 months, and all individuals completed 6-month BPaL\/M treatment with microbiological and clinical cure as of last follow-up (mean 8 months). <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p> Six-month all-oral BPaL\/M regimens appeared effective in these individuals, but delays in drug susceptibility testing and poor medication access led to prolonged isolation, hospitalizations, and overall treatment duration. To fully realize the patient and health system benefits of BPaL\/M treatment in Canada, streamlining laboratory testing and medication access must be prioritized. <\/jats:p><\/jats:sec>","DOI":"10.3138\/jammi-2024-0034","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T16:41:26Z","timestamp":1744303286000},"page":"192-202","source":"Crossref","is-referenced-by-count":0,"title":["Treatment of drug-resistant tuberculosis with bedaquiline, pretomanid, linezolid with or without moxifloxacin (BPaL\/M): Feasibility and implementation challenges in western Canada"],"prefix":"10.3138","volume":"10","author":[{"given":"Paige","family":"Muir","sequence":"first","affiliation":[{"name":"Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria J","family":"Cook","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Tuberculosis Services, BC Centre for Disease Control, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inna","family":"Sekirov","sequence":"additional","affiliation":[{"name":"BCCDC Public Health Laboratory, BC Centre for Disease Control, Vancouver, British Columbia, Canada"},{"name":"Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Johnston","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Tuberculosis Services, BC Centre for Disease Control, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William J","family":"Connors","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Tuberculosis Services, BC Centre for Disease Control, Vancouver, British Columbia, Canada"},{"name":"Division of Infectious Diseases, St. Paul's Hospital, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1696","reference":[{"key":"r1","unstructured":"Cancer Therapy Evaluation Program. Common terminology criteria for adverse events (CTCAE) version 5.0. Washington, DC: U.S. Department of Health and Human Services; 2017."},{"key":"r2","unstructured":"The end TB strategy. World Health Organization. https:\/\/www.who.int\/publications\/i\/item\/WHO-HTM-TB-2015.19 (Accessed February 28, 2024)."},{"volume-title":"Guidelines for the programmatic management of drug-resistant tuberculosis: Emergency update 2008","year":"2008","key":"r3"},{"key":"r4","unstructured":"WHO announces updated definitions of extensively drug-resistant tuberculosis. World Health Organization. https:\/\/www.who.int\/news\/item\/27-01-2021-who-announces-updated-definitions-of-extensively-drug-resistant-tuberculosis (Accessed December 10, 2024)."},{"volume-title":"Module 4: treatment\u2014drug-resistant tuberculosis treatment, 2022 update","author":"WHO consolidated guidelines on tuberculosis","key":"r5"},{"key":"r6","unstructured":"Global tuberculosis report 2022, 2.3 Drug-resistant TB. World Health Organization. https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2022\/tb-disease-burden\/2-3-drug-resistant-tb#:\u223c:text=Globally%2C%20the%20estimated%20proportion%20of,in%202021%20(Fig.%202.3. (Accessed June 16, 2024)."},{"key":"r7","unstructured":"Tuberculosis surveillance in Canada summary report: 2012-2021. Public Health Agency of Canada. https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/diseases-conditions\/tuberculosis-surveillance-canada-summary-2012-2021.html (Accessed January 20, 2024)."},{"volume-title":"WHO consolidated guidelines on drug-resistant tuberculosis treatment","year":"2019","key":"r8"},{"issue":"3","key":"r9","doi-asserted-by":"crossref","first-page":"e0119332","DOI":"10.1371\/journal.pone.0119332","volume":"10","author":"Chung-Delgado K","year":"2015","journal-title":"PLoS One"},{"issue":"11","key":"r10","doi-asserted-by":"crossref","first-page":"e27610","DOI":"10.1371\/journal.pone.0027610","volume":"6","author":"Chung-Delgado K","year":"2011","journal-title":"PLoS One"},{"issue":"9322","key":"r11","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1016\/S0140-6736(02)08830-X","volume":"359","author":"Su\u00e1rez PG","year":"2002","journal-title":"Lancet"},{"key":"r12","unstructured":"CDC Estimates for TB Treatment Costs (in 2020 U.S. Dollars). Centers for Disease Control and Prevention. https:\/\/www.cdc.gov\/tb\/publications\/infographic\/appendix.htm (Accessed May 17, 2024)."},{"issue":"25","key":"r13","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1056\/NEJMoa2117166","volume":"387","author":"Nyang'wa B-T","year":"2022","journal-title":"N Engl J Med"},{"issue":"24","key":"r14","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1056\/NEJMc2009939","volume":"382","author":"Conradie F","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"r15","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa2119430","volume":"387","author":"Conradie F","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"r16","first-page":"109","volume":"6","author":"Brode SK","year":"2022","journal-title":"Can J Respir Crit Care Sleep Med"},{"issue":"7","key":"r17","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/cid\/ciad312","volume":"77","author":"Haley CA","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"1","key":"r18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.14745\/ccdr.v49i01a04","volume":"49","author":"Connors W","year":"2023","journal-title":"Can Commun Dis Rep"},{"key":"r19","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/j.ijid.2019.02.027","volume":"80","author":"K\u00f6ser C","year":"2019","journal-title":"Int J Infect Dis"},{"volume-title":"Technical report on critical concentrations for TB drug susceptibility testing of medicines used in the treatment of drug-resistant TB","year":"2018","key":"r20"},{"issue":"1","key":"r21","first-page":"33","volume":"6","author":"Marcel AB","year":"2022","journal-title":"Can J Respir Crit Care Sleep Med"},{"key":"r22","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00621-2021","volume":"59","author":"Chesov E","year":"2022","journal-title":"Eur Respir J"},{"key":"r23","doi-asserted-by":"crossref","first-page":"e972","DOI":"10.1016\/S2666-5247(23)00172-6","volume":"4","author":"Derendinger B","year":"2023","journal-title":"Lancet Microbe"},{"issue":"8","key":"r24","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.3201\/eid3008.240541","volume":"30","author":"McQuaid C","year":"2024","journal-title":"Emerg Infect Dis"},{"key":"r25","unstructured":"Tuberculosis manual. Vancouver, BC, Canada: BC Centre for Disease Control; 2019. http:\/\/www.bccdc.ca\/health-professionals\/clinical-resources\/communicable-disease-control-manual\/tuberculosis (Accessed August 1, 2024)."},{"key":"r26","first-page":"248","volume":"6","author":"Cooper R","year":"2022","journal-title":"Can J Respir Crit Care Sleep Med"},{"key":"r27","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jinf.2018.07.007","volume":"77","author":"Alene KA","year":"2018","journal-title":"J Infect"},{"key":"r28","unstructured":"Medical access to artesunate or quinine for malaria treatment streamlined in Canada through the Canadian Malaria Network (CMN). Public Health Agency of Canada. https:\/\/www.canada.ca\/en\/public-health\/services\/travel-health\/medical-access-artesunate-quinine-malaria-treatment.html (Accessed December 10, 2024)."},{"issue":"12","key":"r29","doi-asserted-by":"crossref","first-page":"e0001337","DOI":"10.1371\/journal.pgph.0001337","volume":"2","author":"Sweeney S","year":"2022","journal-title":"PLOS Glob Public Health"},{"issue":"5","key":"r30","doi-asserted-by":"crossref","first-page":"e1004401","DOI":"10.1371\/journal.pmed.1004401","volume":"21","author":"James LP","year":"2024","journal-title":"PLoS Med"}],"container-title":["Journal of the Association of Medical Microbiology and Infectious Disease Canada"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/utppublishing.com\/doi\/pdf\/10.3138\/jammi-2024-0034","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T13:34:04Z","timestamp":1752240844000},"score":1,"resource":{"primary":{"URL":"https:\/\/utppublishing.com\/doi\/10.3138\/jammi-2024-0034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6,27]]}},"alternative-id":["10.3138\/jammi-2024-0034"],"URL":"https:\/\/doi.org\/10.3138\/jammi-2024-0034","relation":{},"ISSN":["2371-0888"],"issn-type":[{"type":"electronic","value":"2371-0888"}],"subject":[],"published":{"date-parts":[[2025,6,27]]}}}